BRPI0613067A2 - composições tópicas para alìvio da dor de n,2,3-trimetil-2-isopropilbutamida e métodos de uso das mesmas - Google Patents
composições tópicas para alìvio da dor de n,2,3-trimetil-2-isopropilbutamida e métodos de uso das mesmas Download PDFInfo
- Publication number
- BRPI0613067A2 BRPI0613067A2 BRPI0613067-4A BRPI0613067A BRPI0613067A2 BR PI0613067 A2 BRPI0613067 A2 BR PI0613067A2 BR PI0613067 A BRPI0613067 A BR PI0613067A BR PI0613067 A2 BRPI0613067 A2 BR PI0613067A2
- Authority
- BR
- Brazil
- Prior art keywords
- pain
- topical
- composition
- compositions
- trimethyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 119
- 208000002193 Pain Diseases 0.000 title claims abstract description 102
- 230000036407 pain Effects 0.000 title claims abstract description 102
- 230000000699 topical effect Effects 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 43
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 239000000853 adhesive Substances 0.000 claims abstract description 29
- 230000001070 adhesive effect Effects 0.000 claims abstract description 29
- 239000000499 gel Substances 0.000 claims abstract description 19
- 239000006071 cream Substances 0.000 claims abstract description 10
- 239000006260 foam Substances 0.000 claims abstract description 4
- 239000000017 hydrogel Substances 0.000 claims description 3
- 208000000029 referred pain Diseases 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 description 33
- 238000011282 treatment Methods 0.000 description 16
- 239000013543 active substance Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 238000001467 acupuncture Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 5
- 208000034656 Contusions Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000554 physical therapy Methods 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010006002 Bone pain Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- -1 pH regulators Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 229940100611 topical cream Drugs 0.000 description 2
- 229940042129 topical gel Drugs 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010034246 Pelvic fractures Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940105606 oxycontin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000013133 post surgical procedure Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72984405P | 2005-10-24 | 2005-10-24 | |
| US60/729,844 | 2005-10-24 | ||
| PCT/US2006/040576 WO2007050369A2 (en) | 2005-10-24 | 2006-10-16 | Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0613067A2 true BRPI0613067A2 (pt) | 2010-12-21 |
Family
ID=37968368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0613067-4A BRPI0613067A2 (pt) | 2005-10-24 | 2006-10-16 | composições tópicas para alìvio da dor de n,2,3-trimetil-2-isopropilbutamida e métodos de uso das mesmas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070093555A1 (enExample) |
| EP (1) | EP1940377A4 (enExample) |
| JP (2) | JP5128483B2 (enExample) |
| KR (1) | KR20080035637A (enExample) |
| CN (1) | CN101534805A (enExample) |
| AR (1) | AR058141A1 (enExample) |
| AU (1) | AU2006306563B2 (enExample) |
| BR (1) | BRPI0613067A2 (enExample) |
| CA (1) | CA2614345C (enExample) |
| MX (1) | MX2008000486A (enExample) |
| NZ (1) | NZ564014A (enExample) |
| RU (1) | RU2407522C2 (enExample) |
| TW (1) | TWI372047B (enExample) |
| WO (1) | WO2007050369A2 (enExample) |
| ZA (1) | ZA200711041B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080035637A (ko) * | 2005-10-24 | 2008-04-23 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 엔,2,3-트리메틸-2-이소프로필부타미드의 국소 통증 경감조성물 및 그의 사용 방법 |
| WO2011133177A1 (en) * | 2010-04-21 | 2011-10-27 | Teikoku Pharma Usa, Inc. | Local anesthetic emulsion compositions and methods of making and using the same |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| KR101831290B1 (ko) | 2013-10-07 | 2018-02-22 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물 |
| KR101891185B1 (ko) | 2013-10-07 | 2018-08-24 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물 |
| US20160158393A1 (en) * | 2014-02-21 | 2016-06-09 | Avadim Technologies, Inc. | Method for Improving Health Outcomes |
| CA2939940C (en) | 2014-02-21 | 2023-10-03 | Avadim Technologies, Inc. | Method for maintenance of urethral catheters |
| CA3143518A1 (en) | 2019-06-12 | 2020-12-17 | Avadim Health Ip, Inc. | Compositions and methods for the antiseptic cleansing and biofilms treatment of mammalian tissue |
| WO2020257650A1 (en) * | 2019-06-19 | 2020-12-24 | Ganio Carl | Formulations using lithium to treat gout arthropathy |
| KR102621024B1 (ko) * | 2023-09-12 | 2024-01-05 | (주)진코스텍 | 심미감 및 피부 흡수력이 개선된 하이드로겔 패치 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH10359A (en) | 1971-02-04 | 1977-01-05 | Wilkinson Sword Ltd | N-substituted-p-methane-3-carboxamides having physiological cooling activity and compositions containing them |
| US4193936A (en) | 1971-02-04 | 1980-03-18 | Wilkinson Sword Limited | N-substituted paramenthane carboxamides |
| US4150052A (en) * | 1971-02-04 | 1979-04-17 | Wilkinson Sword Limited | N-substituted paramenthane carboxamides |
| US4060091A (en) | 1972-01-28 | 1977-11-29 | Wilkinson Sword Limited | Tobacco and tobacco-containing manufactures containing an ingredient having physiological cooling activity |
| US4059118A (en) | 1972-01-28 | 1977-11-22 | Wilkinson Sword Limited | Tobacco and tobacco-containing manufactures containing an ingredient having physiological cooling activity |
| US4033994A (en) * | 1972-01-28 | 1977-07-05 | Wilkinson Sword Limited | Substituted p-menthanes |
| GB1421743A (en) | 1972-04-18 | 1976-01-21 | Wilkinson Sword Ltd | Ingestible topical and other compositions |
| US4153679A (en) | 1972-04-18 | 1979-05-08 | Wilkinson Sword Limited | Acyclic carboxamides having a physiological cooling effect |
| CA1027347A (en) | 1972-07-20 | 1978-03-07 | David G. Rowsell | Compounds having a physiological cooling effect and compositions containing them |
| BE802469A (fr) * | 1972-07-20 | 1974-01-18 | Wilkinson Sword Ltd | Perfectionnements apportes et/ou relatifs a des composes exercant un effet refrigerant physiologique et compositions contenant ceux-ci |
| GB1434728A (en) * | 1972-09-27 | 1976-05-05 | Wilkinson Sword Ltd | Compositions and articles containing phospine oxides having a physiological cooling effect and phosphine oxides for use therein |
| US4070449A (en) * | 1972-10-24 | 1978-01-24 | Wilkinson Sword Limited | Compounds having a physiological cooling effect and compositions containing them |
| US4034109A (en) * | 1973-01-18 | 1977-07-05 | Wilkinson Sword Limited | Compounds having a physiological cooling effect and compositions containing them |
| US4296093A (en) * | 1973-04-16 | 1981-10-20 | Wilkinson Sword Limited | Cyclic carboxamides having a physiological cooling effect |
| US4172887A (en) * | 1973-11-30 | 1979-10-30 | L'oreal | Hair conditioning compositions containing crosslinked polyaminopolyamides |
| JPS5888334A (ja) * | 1981-11-20 | 1983-05-26 | Takasago Corp | ３−ｌ−メントキシプロパン−１、２−ジオ−ル |
| US5120544A (en) | 1989-06-19 | 1992-06-09 | Henley International, Inc. | Crosslinked hydrogel and method for making same |
| US5270358A (en) | 1989-12-28 | 1993-12-14 | Minnesota Mining And Manufacturing Company | Composite of a disperesed gel in an adhesive matrix |
| US5148804A (en) * | 1990-06-28 | 1992-09-22 | Hill Dennis M | Device, system, and methods for applying cryotherapy |
| JP3115625B2 (ja) | 1991-03-30 | 2000-12-11 | 帝國製薬株式会社 | リドカイン含有外用貼付剤 |
| DE4110973A1 (de) * | 1991-04-05 | 1992-10-08 | Haarmann & Reimer Gmbh | Mittel mit physiologischem kuehleffekt und fuer diese mittel geeignete wirksame verbindungen |
| US5160328A (en) | 1991-08-07 | 1992-11-03 | Ndm Acquisition Corp. | Hydrogel bandage |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ES2105293T3 (es) * | 1992-06-17 | 1997-10-16 | Procter & Gamble | Composiciones refrescantes con efecto irritante reducido. |
| CA2160874C (en) * | 1993-04-30 | 1999-05-11 | William Fletcher Beck | Nasal aromatic releasing compositions |
| US5760085A (en) * | 1993-04-30 | 1998-06-02 | The Procter & Gamble Company | Topical aromatic releasing compositions |
| NZ250994A (en) | 1993-05-27 | 1995-09-26 | Ndm Acquisition Corp | Wound dressing comprising a hydrogel layer bound to a porous backing layer which is bound to a thin film layer by adhesive |
| US5423737A (en) | 1993-05-27 | 1995-06-13 | New Dimensions In Medicine, Inc. | Transparent hydrogel wound dressing with release tab |
| JP2978043B2 (ja) * | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | （２ｓ）−３−｛（１ｒ，２ｓ，５ｒ）−［ ５−メチル−２−（１−メチルエチル）シクロヘキシル ］オキシ｝−１，２−プロパンジオール，その製造方法および用途 |
| US5407665A (en) * | 1993-12-22 | 1995-04-18 | The Procter & Gamble Company | Ethanol substitutes |
| US5536263A (en) | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
| JP3241542B2 (ja) * | 1994-07-29 | 2001-12-25 | 高砂香料工業株式会社 | （−）−ｎ−イソプレゴールの精製方法及びその方法で得られた（−）−ｎ−イソプレゴールを含有するシトラス系香料組成物 |
| KR100209469B1 (ko) * | 1994-10-05 | 1999-07-15 | 나까도미 히로다카 | N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형 제제 |
| US5853768A (en) * | 1995-03-01 | 1998-12-29 | Altadonna; James | Topical preparation and method for pain relief |
| DE69625549T2 (de) * | 1995-06-27 | 2003-05-15 | Kao Corp., Tokio/Tokyo | Pflaster mit wasserlöslicher Klebeschicht |
| US6039940A (en) | 1996-10-28 | 2000-03-21 | Ballard Medical Products | Inherently antimicrobial quaternary amine hydrogel wound dressings |
| US6769428B2 (en) | 1997-01-29 | 2004-08-03 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| US6244265B1 (en) * | 1997-01-29 | 2001-06-12 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| WO1999007342A1 (en) * | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6455080B1 (en) * | 1997-12-29 | 2002-09-24 | Wm. Wrigley Jr., Company | Chewing gum containing controlled release acyclic carboxamide and method of making |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| JP3450680B2 (ja) | 1997-10-28 | 2003-09-29 | 高砂香料工業株式会社 | パラ−メンタン−３，８−ジオールの製造方法 |
| EP1034161B2 (fr) * | 1997-11-27 | 2006-03-15 | Firmenich Sa | Nouveaux composes derives du menthol et leur utilisation en tant qu'agent rafraichissant |
| JP4017758B2 (ja) * | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | 冷感剤組成物 |
| US6656456B2 (en) * | 1998-11-23 | 2003-12-02 | The Procter & Gamble Company | Skin deodorizing compositions |
| US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
| EP1541039B1 (en) | 1999-03-31 | 2008-01-02 | Firmenich Sa | Flavour composition comprising cubebol and a further refreshing agent |
| US6267974B1 (en) * | 1999-04-16 | 2001-07-31 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with sensate mixtures based on isopulegol |
| US6348212B2 (en) | 1999-05-18 | 2002-02-19 | Lectec Corporation | Treating traumatic burns or blisters of the skin |
| US6455065B1 (en) | 1999-05-18 | 2002-09-24 | Lectec Corporation | Therapeutic method for treating acne or isolated pimples and adhesive patch therefor |
| US6296869B1 (en) | 1999-07-30 | 2001-10-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Adhesive cosmetic patch containing alpha or beta hydroxy acids |
| EP1217975A1 (en) * | 1999-09-08 | 2002-07-03 | Watson Pharmaceuticals, Inc. | Using quaternary ammonium salts for transdermal drug delivery |
| EP1227788B1 (en) | 1999-11-12 | 2010-08-11 | The Procter & Gamble Company | Oral compositions containing stannous ions |
| US6677391B1 (en) | 1999-12-08 | 2004-01-13 | The Procter & Gamble Company | Tartar control denture adhesive compositions |
| ATE380474T1 (de) * | 2000-05-23 | 2007-12-15 | Nestle Sa | Verwendung von alpha-ketoenaminderivaten als kühlende mittel |
| AU2001268451A1 (en) * | 2000-06-13 | 2001-12-24 | Fd Management, Inc. | Cosmetic composition for stressed skin under extreme conditions |
| US6497859B1 (en) | 2000-11-17 | 2002-12-24 | Noville Inc. | Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same |
| US6391886B1 (en) * | 2000-12-04 | 2002-05-21 | The Procter & Gamble Company | Oral compositions having improved consumer aesthetics |
| US20020143047A1 (en) * | 2001-01-05 | 2002-10-03 | Galer Bradley S. | Methods for treating indomethacin responsive headaches |
| US6761900B2 (en) * | 2001-03-12 | 2004-07-13 | Teikoku Pharma Usa, Inc. | Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| US6514484B2 (en) | 2001-03-19 | 2003-02-04 | The Procter & Gamble Company | Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
| EP1245240A1 (en) | 2001-03-30 | 2002-10-02 | The Procter & Gamble Company | Skin-compatible hydrogel adhesives and personal care products containing them |
| CN100408016C (zh) | 2001-06-25 | 2008-08-06 | 宝洁公司 | 口腔组合物 |
| US20030175328A1 (en) * | 2002-03-06 | 2003-09-18 | Adi Shefer | Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
| JP2004059474A (ja) | 2002-07-26 | 2004-02-26 | T Hasegawa Co Ltd | ｐ−メンタン誘導体およびこれを含有する冷感剤 |
| GB0221697D0 (en) | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
| GB0315974D0 (en) | 2003-07-08 | 2003-08-13 | Coolanalgesia Ltd | Cooling device for pain relief |
| WO2005060550A2 (en) * | 2003-12-11 | 2005-07-07 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating skin wounds |
| US7482378B2 (en) * | 2004-05-28 | 2009-01-27 | Millenium Specialty Chemicals, Inc. | Physiological cooling compositions |
| PL1833443T3 (pl) * | 2005-01-04 | 2012-04-30 | Teikoku Pharma Usa Inc | Miejscowy preparat chłodzący w postaci plastra |
| US20070259354A1 (en) * | 2005-10-11 | 2007-11-08 | Senomyx, Inc. | Optimized trpm8 nucleic acid sequences and their use in cell based assays and test kits to identify trpm8 modulators |
| KR20080035637A (ko) * | 2005-10-24 | 2008-04-23 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 엔,2,3-트리메틸-2-이소프로필부타미드의 국소 통증 경감조성물 및 그의 사용 방법 |
| US20070185237A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
-
2006
- 2006-10-16 KR KR1020087003791A patent/KR20080035637A/ko not_active Ceased
- 2006-10-16 RU RU2008117760/15A patent/RU2407522C2/ru not_active IP Right Cessation
- 2006-10-16 ZA ZA200711041A patent/ZA200711041B/xx unknown
- 2006-10-16 AU AU2006306563A patent/AU2006306563B2/en not_active Ceased
- 2006-10-16 WO PCT/US2006/040576 patent/WO2007050369A2/en not_active Ceased
- 2006-10-16 BR BRPI0613067-4A patent/BRPI0613067A2/pt not_active IP Right Cessation
- 2006-10-16 US US11/582,130 patent/US20070093555A1/en not_active Abandoned
- 2006-10-16 MX MX2008000486A patent/MX2008000486A/es active IP Right Grant
- 2006-10-16 NZ NZ564014A patent/NZ564014A/en not_active IP Right Cessation
- 2006-10-16 JP JP2008536741A patent/JP5128483B2/ja not_active Expired - Fee Related
- 2006-10-16 EP EP06826119A patent/EP1940377A4/en not_active Withdrawn
- 2006-10-16 CN CNA2006800234582A patent/CN101534805A/zh active Pending
- 2006-10-16 CA CA76A patent/CA2614345C/en not_active Expired - Fee Related
- 2006-10-23 TW TW095138942A patent/TWI372047B/zh not_active IP Right Cessation
- 2006-10-23 AR ARP060104625A patent/AR058141A1/es unknown
-
2012
- 2012-06-13 JP JP2012133664A patent/JP5508477B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR058141A1 (es) | 2008-01-23 |
| KR20080035637A (ko) | 2008-04-23 |
| CA2614345C (en) | 2013-01-08 |
| CA2614345A1 (en) | 2007-05-03 |
| AU2006306563A1 (en) | 2007-05-03 |
| AU2006306563B2 (en) | 2009-10-01 |
| ZA200711041B (en) | 2009-08-26 |
| TW200731965A (en) | 2007-09-01 |
| JP2012197301A (ja) | 2012-10-18 |
| JP5128483B2 (ja) | 2013-01-23 |
| RU2407522C2 (ru) | 2010-12-27 |
| WO2007050369A3 (en) | 2009-04-30 |
| EP1940377A2 (en) | 2008-07-09 |
| JP2009515829A (ja) | 2009-04-16 |
| RU2008117760A (ru) | 2009-12-10 |
| WO2007050369A2 (en) | 2007-05-03 |
| TWI372047B (en) | 2012-09-11 |
| NZ564014A (en) | 2011-10-28 |
| US20070093555A1 (en) | 2007-04-26 |
| CN101534805A (zh) | 2009-09-16 |
| EP1940377A4 (en) | 2010-12-08 |
| JP5508477B2 (ja) | 2014-05-28 |
| MX2008000486A (es) | 2008-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5508477B2 (ja) | Ｎ，２，３−トリメチル−２−イソプロピルブタナミドの局所用疼痛緩和用組成物並びにその使用法 | |
| US6528076B2 (en) | Topical compositions and methods for treating pain | |
| ES2620389T3 (es) | Formulaciones tópicas de co-enzima Q10 y tratamiento de dolor, fatiga y heridas | |
| US12109181B2 (en) | Lidocaine patch and methods of use thereof | |
| WO2009067535A1 (en) | Topical composition for treating pain | |
| US9186273B2 (en) | Methods of treating pains associated with neuroma, nerve entrapment, and other conditions | |
| WO2008027203A2 (en) | Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue | |
| AU3662701A (en) | Multi-purpose drug and heat therapy treatment system | |
| CN103271997B (zh) | 一种温经通络活血止痛热磁治疗贴 | |
| US9186334B2 (en) | Heat assisted lidocaine and tetracaine for transdermal analgesia | |
| WO2005037347A2 (en) | Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents | |
| AU2015200633A1 (en) | Methods for treating pains associated with neuroma, nerve entrapment, and other conditions | |
| RU2284176C2 (ru) | Способ лечения больных с миофасциальным болевым дисфункциональным синдромом | |
| CN119868435B (zh) | 治疗陈旧性踝关节扭伤的中药组合物和中药膏摩剂 | |
| US20060182819A1 (en) | Soap scent patch and treatment for muscle spasm and pain | |
| RU2341285C1 (ru) | Набор для лечения заболеваний, вызванных патологическим изменением хрящевой и/или костной ткани, и способ его применения | |
| JP2009191073A (ja) | 脂肪減少用外用剤及び脂肪減少装置 | |
| CA2734300A1 (en) | Heat assisted lidocaine and tetracaine for transdermal analgesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |